Rifampicin shortage — NZ supply status & alternatives

Rifampicin

—

🇦🇺 AUST R 10113 · Sanofi-Aventis Australia Pty Ltd

In supply · Australia

WHO Essential Medicine

RIFADIN rifampicin

In supply · 🇦🇺 Australia · short in🇩🇪 DE🇳🇿 NZ🇳🇴 NO

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$7.54DPMQ A$108.72details →

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Product attributes reference data we hold

Active ingredient (INN)	Rifampicin
Brand names	RIFADIN rifampicin
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper
WHO Essential Medicine	Yes (2023)
Controlled substance	No
Marketing-authorisation holders	Generics (UK) Limited, Sanofi-Aventis Australia Pty Ltd, Alphapharm Pty Ltd
Registrations on file	8
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$7.54

AEMP

Dispensed (DPMQ)

A$108.72

incl. fees

Pack

rifampicin 300 mg capsule, 10

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

5 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk✓ 4 WHO-prequalified

Hebei Xingang Pharmaceutical Co LtdMacleods Pharmaceuticals LtdLupin LtdOlon S.p.A.Olon SPA

Manufacturing countries: India, Italy · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇳🇿

New Zealand

Pharmac · 10h ago

High

🇳🇴

Norway

NOMA · 3d ago

Medium

🇩🇪

Germany

BfArM · 10d ago

Medium

🇬🇷

EOF · 3mo ago

Resolved

🇦🇺

Australia

TGA · just now

Resolved

Verified timeline regulator events

🇳🇴 20 Aug 2026

medium reported

🇳🇿 5 May 2026

high reported

🇳🇴 4 May 2026

medium reported

🇩🇪 27 Apr 2026

medium reported

🇳🇴 25 Mar 2026

medium reported

🇳🇴 16 Mar 2026

medium reported

Sources official regulators

🇦🇺

TGA

verified just now

verify ↗

🇳🇿

Pharmac

verified 10h ago

verify ↗

🇳🇴

NOMA

verified 3d ago

verify ↗

🇩🇪

BfArM

verified 10d ago

verify ↗

🇬🇷

EOF

verified 3mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders8 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
RIFAMPICIN CAPSULES 150MG	150MG	capsule	🇬🇧 GB	Generics (UK) Limited	Active
RIFAMPICIN CAPSULES 300MG	300MG	capsule	🇬🇧 GB	Generics (UK) Limited	Active
RIFADIN rifampicin	20mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active
Rimycin	150 mg	—	🇦🇺 AU	Alphapharm Pty Ltd	Active
Rimycin	300 mg	—	🇦🇺 AU	Alphapharm Pty Ltd	Active
RIFADIN rifampicin	600mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active
RIFADIN rifampicin	150mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active
RIFADIN rifampicin	300mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.